12:21 AM EDT, 10/08/2026 (MT Newswires) -- Valneva (VLA.PA) received information that the UK's Medicines and Healthcare products Regulatory Agency revoked the marketing authorization for Ixchiq, its chikungunya vaccine. The specialty vaccine company said Wednesday that the regulator's decision followed the UK Commission on Human Medicines' additional benefit-risk assessment of the vaccine for travelers. It noted that the assessment considered previous safety data and was not due to newly discovered safety signals. Valneva added that Ixchiq, which was launched in the UK in mid-2025, has not been actively distributed in the country for several months. The company also assured that the withdrawal of the UK marketing authorization has no impact on its licenses in the European Union, Canada and Brazil, among other territories.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.